Under embargo for
17:00 EST/22:00 GMT 8 January 2014
Cambridgeshire, UK, 8 January 2014 ...
Lumora, a provider of state-of-the-art molecular diagnostic products for the clinical and industrial market, has developed a new test for C. difficile which is more than twice as fast as current clinical techniques.
The research, which is published in PLOS ONE, describes how C. difficile was detected from a stool sample using a recently developed rapid, novel and low complexity extraction process called Heat Elution (HE). Using heat elution, the sample preparation process took around ten minutes compared to nearly an hour for traditional techniques.
The test was evaluated in a pilot study on clinical fecal samples and was developed using HE in conjunction with an Isothermal Amplification and Lumora’s BART technology
The HE- -BART method showed 95.5% sensitivity and 100% specificity against a gold standard reference method using cytotoxigenic culture and also a silica-based robotic extraction followed by PCR to control for storage. From sample to result, the HE- -BART method typically took 50 minutes, whereas the PCR method took over 2.5 hours.
The research also compared this new approach with another commercially available method, Illumigene (Meridian Bioscience, OH), and found the combined HE- -BART method had 87.2% sensitivity and 100% specificity, compared to 76.6% 14 and 100%, respectively, for Illumigene.
Laurence Tisi, CEO of Lumora, said: “This research shows the strength of our technology and work flow. By combining proven technologies such as BART with our new sample preparation technology, we have developed a highly effective and rapid test for a common bacteria which can be responsible for significant ill health.”
Hayden Jeffreys, Commercial Director of Lumora, said: “The commercial opportunities for this test are significant. Using this test will enable healthcare professionals to quickly and accurately test suspected cases and take appropriate action to limit the further spread. Furthermore, by showing its effectiveness against one of the most commonly used diagnostics we believe this should lead to significant interest.”
This deal follows a series of milestones for Lumora this year, including a deal with Promega to supply reagents, a deal with Biogal to provide veterinary diagnostics, a partnership with FIND (Foundation for Innovative New Diagnostics) to develop a novel malaria diagnostic, a new fundraising round and the appointment of new team members including a new commercial director and Chairman.
For further information please contact:
Tony Stephenson, Director
Tel: +44 (0)7899 796655
Notes to Editors:
The full PLOS One paper can be found at http://dx.plos.org/10.1371/journal.pone.0083808
Lumora is a successful provider of state-of-the-art molecular diagnostic products into both the clinical and non clinical or industrial markets. Lumora’s easy to deploy and use technology can be employed in fields as diverse as food safety testing, and medical diagnostics. The Company is very active in licensing its technology and development partners include international biotechnology, clinical diagnostic and industrial microbiology companies.
Lumora’s corporate office is based just outside of Cambridge, England. The Company's investors include; Tate Lyle Ventures LP, Cambridge Enterprise (University of Cambridge), and Catapult Venture Managers Ltd.